179 related articles for article (PubMed ID: 17220638)
1. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia.
Savica V; Calò LA; Caldarera R; Cavaleri A; Granata A; Santoro D; Savica R; Muraca U; Mallamace A; Bellinghieri G
Nephron Physiol; 2007; 105(3):p52-5. PubMed ID: 17220638
[TBL] [Abstract][Full Text] [Related]
2. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
[TBL] [Abstract][Full Text] [Related]
3. A new approach to the evaluation of hyperphosphatemia in chronic kidney disease.
Savica V; Calò LA; Granata A; Caldarera R; Cavaleri A; Santoro D; Monardo P; Savica R; Muraca U; Bellinghieri G
Clin Nephrol; 2007 Oct; 68(4):216-21. PubMed ID: 17969488
[TBL] [Abstract][Full Text] [Related]
4. Salivary phosphate secretion in chronic kidney disease.
Savica V; Calò L; Santoro D; Monardo P; Granata A; Bellinghieri G
J Ren Nutr; 2008 Jan; 18(1):87-90. PubMed ID: 18089451
[TBL] [Abstract][Full Text] [Related]
5. Salivary glands: a new player in phosphorus metabolism.
Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
[TBL] [Abstract][Full Text] [Related]
6. Salivary levels of calcium, phosphorus, potassium, albumin and correlation with serum biomarkers in hemodialysis patients.
Rodrigues VP; Franco MM; Marques CP; de Carvalho RC; Leite SA; Pereira AL; Benatti BB
Arch Oral Biol; 2016 Feb; 62():58-63. PubMed ID: 26655748
[TBL] [Abstract][Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
Pai AB; Smeeding JE; Brook RA
Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
[TBL] [Abstract][Full Text] [Related]
9. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.
Savica V; Calò LA; Monardo P; Davis PA; Granata A; Santoro D; Savica R; Musolino R; Comelli MC; Bellinghieri G
J Am Soc Nephrol; 2009 Mar; 20(3):639-44. PubMed ID: 19020004
[TBL] [Abstract][Full Text] [Related]
10. The clinical management of hyperphosphatemia.
Ritz E
J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study.
Qunibi WY; Nolan CR
Kidney Int Suppl; 2004 Sep; (90):S33-8. PubMed ID: 15296505
[TBL] [Abstract][Full Text] [Related]
12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
13. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
Takahashi Y; Tanaka A; Nakamura T; Fukuwatari T; Shibata K; Shimada N; Ebihara I; Koide H
Kidney Int; 2004 Mar; 65(3):1099-104. PubMed ID: 14871431
[TBL] [Abstract][Full Text] [Related]
14. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
15. Phosphorus management in end-stage renal disease.
Finn WF
Semin Dial; 2005; 18(1):8-12. PubMed ID: 15663754
[TBL] [Abstract][Full Text] [Related]
16. New developments in the management of hyperphosphatemia in chronic kidney disease.
McIntyre CW
Semin Dial; 2007; 20(4):337-41. PubMed ID: 17635825
[TBL] [Abstract][Full Text] [Related]
17. Understanding and managing hyperphosphatemia in patients with chronic renal disease.
Malluche HH; Monier-Faugere MC
Clin Nephrol; 1999 Nov; 52(5):267-77. PubMed ID: 10584989
[TBL] [Abstract][Full Text] [Related]
18. Hyperphosphatemia among end-stage renal disease patients in developing countries: a forgotten issue?
Afifi A; El-Sayed H; El-Setouhi M; Ahmed H; Khalifa N
Hemodial Int; 2005 Oct; 9(4):409-15. PubMed ID: 16219062
[TBL] [Abstract][Full Text] [Related]
19. Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD).
Qunibi WY
Kidney Int Suppl; 2004 Sep; (90):S8-S12. PubMed ID: 15296501
[TBL] [Abstract][Full Text] [Related]
20. Phosphorus balance with daily dialysis.
Kooienga L
Semin Dial; 2007; 20(4):342-5. PubMed ID: 17635826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]